The implant was well tolerated in all eight patients involved, the release said. It’s designed to substitute daily drop therapy by providing sustained treatment for glaucoma patients over six months.
“Our implant represents a significant advance for the treatment of glaucoma,” Russell Tait, CEO of PolyActiva, said in a statement. “Our goal is to improve the reduction of intraocular pressure by ensuring a constant daily dose of drug for the entire treatment period and offering the opportunity for repeated use. Furthermore, the implant should reduce the frequency of conjunctival hyperemia and corneal surface disease side effects often seen with drop therapy.”
Phase 2 of the trial has been initiated across nine clinical trial sites in Australia, the report said. It will identify the minimum effective dose of latanoprost free acid and confirm the implant’s safety.
Read the full release here.
More articles on surgery centers:
The ASC in 2021: 3 expert predictions on cardiology
10 lowest-paying cities for physicians
ASC valuation multiples continue to rise & more — 12 ASC industry notes
